UrologyNews.net

Urology Xagena

Search results for "Platinum-based chemotherapy"

In the IMvigor 210 study, the investigational cancer immunotherapy Atezolizumab ( MPDL3280A; anti-PD-L1 ) shrank tumors ( objective response rate; ORR; the primary end point of this study ) in people ...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Tecentriq ( Atezolizumab ) for the treatment of people with locally advanced or metastatic urothelial carcinoma ( mUC ...


The efficacy and safety of a combination of chemotherapeutic agent compared with single-agent chemotherapy in the second-line setting of advanced urothelial carcinoma ( UC ) are unclear. Researchers ...


Immunotherapy has shown promising results in first and second line treatment of metastatic bladder cancer in two phase II trials presented at the ESMO ( European Society for Medical Oncology ) Congres ...